Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
J Ren Nutr ; 28(1): 54-63, 2018 01.
Article in English | MEDLINE | ID: mdl-29089279

ABSTRACT

OBJECTIVE: Alterations in the balance between serum n-3 and n-6 polyunsaturated fatty acids (PUFAs) is predictive of cardiovascular events among hemodialysis patients, although little is known about the serum ratio of n-6 arachidonic acid (AA) to n-6 dihomo-γ-linoleic acid (DGLA) in renal failure. We hypothesized that AA/DGLA ratio is altered in hemodialysis patients resulting in poor clinical outcomes. METHODS: This was a single center cohort study in an urban area in Japan with cross-sectional analyses. Subjects were 517 hemodialysis patients and 122 control subjects. The main exposure was serum AA/DGLA ratio, and the main outcome measures were all-cause mortality and cardiovascular events during 5 years. RESULTS: The hemodialysis patients showed a higher median (interquartile range) AA/DGLA ratio than the control subjects (6.46 [5.22-7.81] versus 4.56 [3.74-6.34], P < .001). In a Cox proportional hazard model adjusted for age, sex, dialysis duration, diabetic nephropathy, prior cardiovascular disease, and the ratio of serum n-3 polyunsaturated fatty acids (eicosapentaenoic acid plus docosahexaenoic acid) to AA, the higher quartiles of AA/DGLA ratio were associated with higher risk for all-cause mortality with hazard ratios (95% confidence interval) of 1.50 (0.84-2.76) for quartile 2, 2.10 (1.18-3.86) for quartile 3, and 2.02 (1.10-3.78) for quartile 4 compared with quartile 1. AA/DGLA ratio showed a similar association with the risk of cardiovascular events. CONCLUSIONS: AA/DGLA ratio was elevated in patients with end-stage renal disease requiring hemodialysis, and a high AA/DGLA ratio was an independent predictor of poor clinical outcomes in this population.


Subject(s)
Cardiovascular Diseases/blood , Cardiovascular Diseases/mortality , Fatty Acids, Omega-6/blood , Renal Dialysis/mortality , Aged , Arachidonic Acid/blood , Cardiovascular Diseases/etiology , Cholesterol/blood , Cross-Sectional Studies , Delta-5 Fatty Acid Desaturase , Docosahexaenoic Acids/blood , Eicosapentaenoic Acid/blood , Fatty Acid Desaturases/blood , Female , Follow-Up Studies , Humans , Japan/epidemiology , Kidney Failure, Chronic/blood , Kidney Failure, Chronic/complications , Kidney Failure, Chronic/mortality , Male , Middle Aged , Proportional Hazards Models , Prospective Studies , Renal Dialysis/adverse effects , Risk Factors , Serum Albumin/metabolism , Treatment Outcome
2.
Rinsho Ketsueki ; 54(7): 658-63, 2013 Jul.
Article in Japanese | MEDLINE | ID: mdl-23912350

ABSTRACT

A 30-year-old female developed fever and multiple lymphadenopathy in September 2011. Her symptoms improved with antibiotic treatment. However, she again presented with fever and multiple lymphadenopathy in December 2011. In addition, she suffered from nephrotic syndrome with severe edema. She was therefore hospitalized to undergo detailed examinations. Renal biopsy revealed endocapillary proliferative glomerulonephritis. Since her renal function deteriorated rapidly, she was given steroid pulse therapy with methylprednisolone, followed by maintenance therapy with prednisolone. After treatment, her renal function improved but multiple lymphadenopathy persisted. Biopsy of a left axillary lymph node was then performed and revealed angioimmunoblastic T-cell lymphoma (AITL). She received CHOP therapy but showed no response. Therefore, she was given ESHAP therapy. A partial response was achieved and the nephrotic syndrome also resolved completely. We report this extremely rare case of renal dysfunction due to endocapillary proliferative glomerulonephritis complicated by AITL.


Subject(s)
Glomerulonephritis, Membranoproliferative/therapy , Immunoblastic Lymphadenopathy/therapy , Lymphoma, T-Cell/pathology , Nephrotic Syndrome/therapy , Adult , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Biopsy/methods , Cyclophosphamide/therapeutic use , Doxorubicin/therapeutic use , Female , Glomerulonephritis, Membranoproliferative/complications , Glomerulonephritis, Membranoproliferative/pathology , Humans , Immunoblastic Lymphadenopathy/complications , Immunoblastic Lymphadenopathy/pathology , Lymphoma, T-Cell/complications , Lymphoma, T-Cell/drug therapy , Nephrotic Syndrome/complications , Prednisone/therapeutic use , Treatment Outcome , Vincristine/therapeutic use
3.
J Atheroscler Thromb ; 24(4): 412-421, 2017 Apr 03.
Article in English | MEDLINE | ID: mdl-27629255

ABSTRACT

AIM: The cardiothoracic ratio (CTR) on a chest X-ray is an indicator of cardiac enlargement, although its predictive power for cardiovascular disease (CVD) events in chronic kidney disease is unknown. We examined it in a cohort of hemodialysis patients, as compared with an N-terminal fragment of probrain natriuretic peptide (NT-proBNP). METHOD: This was an observational study with cross-sectional and longitudinal analyses including 517 maintenance hemodialysis patients and 122 healthy control subjects. The main predictors were CTR and serum NT-proBNP, and the main outcome was CVD events in 5 years. RESULTS: At baseline, the hemodialysis patients had higher median (interquartile range) levels of CTR [0.487 (0.457-0.520)] than the control group [0.458 (0.432-0.497)]. In the hemodialysis group, CTR was positively correlated with NT-proBNP (Spearman's r=0.44, P<0.001). During follow-up, 190 CVD events occurred. CTR was significantly associated with the risk of CVD [HR 2.12 (95% CI, 1.38-3.25) for the fourth quartile as compared with the second quartile of CTR] in a multivariate Cox model. In the same model, NT-proBNP (fourth versus first quartile) showed a HR of 3.27 (2.02-5.31). When CTR and NT-proBNP were simultaneously included as predictors, only NT-proBNP remained a significant predictor of CVD events, all-cause mortality and composite of CVD plus all-cause mortality. CONCLUSIONS: We showed that CTR was a significant and independent predictor of CVD in hemodialysis patients. CTR can be used for CVD risk stratification in hemodialysis patients when NT-proBNP is not available.


Subject(s)
Biomarkers/blood , Cardiovascular Diseases/diagnosis , Natriuretic Peptide, Brain/blood , Peptide Fragments/blood , Radiography, Thoracic/methods , Renal Dialysis/adverse effects , Aged , Cardiovascular Diseases/blood , Cardiovascular Diseases/etiology , Case-Control Studies , Cross-Sectional Studies , Female , Humans , Longitudinal Studies , Male , Middle Aged , Predictive Value of Tests , Prospective Studies , Risk Factors
4.
Sci Rep ; 7(1): 4382, 2017 06 29.
Article in English | MEDLINE | ID: mdl-28663544

ABSTRACT

Cognitive impairment is more prevalent in those with decreased kidney function. We tested a hypothesis that an increased homocysteine and/or cerebral small vessel diseases (SVDs) mediate the link between kidney and cognitive functions in a cross-sectional study in 143 type 2 diabetes patients without diagnosis of dementia or prior stroke. The exposure and outcome variables were estimated glomerular filtration rate (eGFR) and cognitive performance evaluated with Modified Mini-Mental State (3 MS) examination, respectively. The candidate mediators were plasma homocysteine concentration, and SVDs including silent cerebral infarction, cerebral microbleed, periventricular hyperintensity, and deep and subcortical white matter hyperintensity by magnetic resonance imaging. In multiple regression models adjusted for 12 potential confounders, eGFR was positively associated with 3 MS score, inversely with homocysteine, but not significantly with the presence of any type of SVD. The association of eGFR with 3 MS remained significant when each of the SVDs was added to the model, whereas it disappeared when homocysteine was included in place of SVD. Mediation analysis indicated nearly significant mediation of homocysteine (P = 0.062) but no meaningful mediations of SVDs (P = 0.842-0.930). Thus, homocysteine, not SVDs, was shown to be the possible mediator between kidney and cognitive functions in patients with type 2 diabetes mellitus.


Subject(s)
Cerebral Small Vessel Diseases/etiology , Cerebral Small Vessel Diseases/psychology , Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/complications , Homocysteine/blood , Kidney Diseases/etiology , Kidney Diseases/physiopathology , Aged , Aged, 80 and over , Biomarkers , Cerebral Small Vessel Diseases/diagnosis , Cognition , Cognitive Dysfunction/diagnosis , Cognitive Dysfunction/etiology , Cognitive Dysfunction/psychology , Female , Glomerular Filtration Rate , Humans , Kidney Diseases/diagnosis , Kidney Function Tests , Male , Middle Aged , Odds Ratio , Prognosis
SELECTION OF CITATIONS
SEARCH DETAIL